MedTrace Logo

A Study to Evaluate Safety, Tolerability and Efficacy of Lytixar™ (LTX-109) on Uncomplicated, Gram-positive, Skin Infection

NCT01223222 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2011-02-16

No results posted yet for this study

Summary

The purpose of this study is to evaluate the safety and tolerability of Lytixar™ applied topically to uncomplicated skin infections.

Three dose levels of Lytixar™ (1%, 2% and 5%) versus placebo will be tested.

Conditions

Interventions

DRUG

LTX-109

Topical administration. 3 times daily. 5 days.

Sponsors & Collaborators

  • Lytix Biopharma AS

    lead INDUSTRY

Principal Investigators

  • Lajos Kemeny, DSc, Prof · St. George Albert Clinic Zeged University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-09-30
Primary Completion
2011-02-28
Completion
2011-02-28

Countries

  • Hungary

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01223222 on ClinicalTrials.gov